Thursday, July 23, 2009

Every Cloud...

Whilst Britain bunkers down in preparation for the so called Swine Flu "pandemic", GlaxoSmithKline hopes to reap the benefit of 18 years of preparation by generating £600M from its Relenza treatment this year.

The British Government has ordered 132 million doses from GSK and Baxter, an American company.

Quite what the profit margin GSK makes on a dose of Relenza is unclear. The company have dismissed rumours that it plans to sell it at £6 a dose, compared to £1 a dose manufacturing cost.

Doubtless our "economically astute" government has negotiated a "good" price!

No comments:

Post a Comment